R&D Sponsored Company Profile: Recursion TechBio Recursion is continuously moving toward increased AI, automation, and machine learning modelling.
Digital A look back at 2023: A Benchling biotech breakfast As we enter the New Year, and set forth into the myriad possibilities and plans of 2024, it pays to pause and reflect.
R&D Talking techbio with NVIDIA: Accelerated computing, NLP, and... As Genentech and NVIDIA enter into a multi-year strategic AI research collaboration to accelerate drug discovery and development, web editor Nicole Raleigh revisits a recent discussion with
News Jazz builds in epilepsy with $1.3bn Actio acquisition Jazz Pharma has dipped its toe into the M&A water again, agreeing to buy rare epilepsy drug developer Actio Bio for $820m upfront.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
